Celonic offers biotech companies use of new GS-CHOvolution cell line expression system
Celonic has signed a commercial license agreement with Revvity for its CHOSOURCE expression platform and TnT transposon technology. The Revvity expression platform will be used in combination with Celonic’s expertise and workflows to enhance the cell line development of monoclonal antibodies (mAbs) and complex proteins.
GS-CHOvolution is based on Revvity’s gene-edited Glutamine Synthetase (GS) knockout Chinese Hamster Ovary (CHO-K1) cGMP-compliant cell line and the TnT transposon technology to accelerate cell line development timelines and to streamline the selection of high expressing clones during cell line development. GS-CHOvolution’s expression platform is a well-established industry standard for biomanufacturing due to its ability to produce high yields of quality therapeutic proteins and is recognized by regulators as suitable for the manufacturing of mAbs and complex proteins.
Biotech and pharma companies can use GS-CHOvolution’s expression system through a simplified license fee model without royalties.
Dr Samanta Cimitan, CEO Celonic Group, commented: “We are delighted to partner with Revvity to provide our customers a state-of-the-art GS expression platform with a track record of success which complements Celonic’s early phase offering. We are committed to bringing our customers of all sizes, expertise, agility and solutions to develop and manufacture life-improving drugs effectively and efficiently.”
Dr Alan Fletcher, Revvity’s senior vice president, life sciences, said: “Celonic and Revvity are likeminded organizations, we both seek to enable our customers and help advance the biotherapeutics of tomorrow. We are very pleased that Celonic has chosen the CHOSOURCE expression platform for their contract development and manufacturing services. Our well-established cGMP manufacturing CHO cell line has over 65 INDs filed globally and empowers companies to accelerate and streamline biotherapeutic development programmes from DNA to clinical manufacturing. But what truly differentiates Revvity is our commitment to the evolution of our platforms and ongoing collaboration with our partners to achieve their current, as well as future, development and manufacturing needs.”
For more information, visit: www.celonic.com
Digital issue: Please click here for more information
